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Abstract
Identification of fungal species in positive blood cultures using conventional methods can be time-consuming, particularly for non-albicans
Candida species, non-Candida yeasts, and moulds. An oligonucleotide array system targeting the internal transcribe spacer (ITS) 1 or 2
region of the rRNA genes was used to analyse prospectively 116 fungus-positive blood cultures [BACTEC Myco/F Lytic bottles (Bec-
ton-Dickinson Microbiology Systems, Sparks, MD, USA)] from 105 patients, and the results were compared with those obtained using
conventional methods. A total of 124 yeast isolates and two mould isolates were identified; these microorganisms (isolate no.) included
C. albicans (50), C. tropicalis (26), C. glabrata (18), C. parapsilosis (14), Cryptococcus neoformans (9), Trichosporon asahii (2), Rhodotorula muci-
laginosa (2), Penicillium marneffei (2) and three other species. Multiple species fungaemia (MSF) was detected in ten samples as opposed
to six detected using conventional methods. In two discrepant samples, antifungal susceptibility testing revealed that the additionally
detected isolate had higher MICs of fluconazole. An isolate reported as Rhodotorula glutinis by the Vitek Yeast Biochemical Card (bio-
Me´rieux Vitek, Marcy l’Etoile, France) was identified as R. mucilaginosa by the array and the identification by array hybridization was con-
firmed by sequence analysis of the ITS region. A test sensitivity of 100% was obtained. The test specificity was 100% according to
examination of 57 blood samples containing non-target fungal species or bacterium only. From the time at which growth was detected
in blood cultures, the entire identification procedure could be completed within 16–24 h.
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Introduction
Bloodstream fungal infection (BFI) has emerged as a world-
wide healthcare problem in recent years because of the grow-
ing number of immunocompromised patients. In addition, the
problem of BFI is complicated by a shift of species distribution
to non-albicans Candida, non-fumigatus Aspergillus, and moulds
other than Aspergillus, which may be resistant to commonly
used antimicrobial agents [1]. As timely antifungal therapy
could improve patient survival, rapid and accurate identifica-
tion of the infecting species is crucial for treating bloodstream
fungal infection. However, commercially available identifica-
tion systems, such as the Vitek Yeast Biochemical Card
(bioMe´rieux Vitek, Marcy l’Etoile, France) and the API system
(bioMe´rieux) require one to several days after isolation for
yeast identification. Incorrect or incomplete identification by
these systems, including clinically important species such as
Candida glabrata and C. krusei, have been reported [2].
A variety of techniques have been proposed to achieve
earlier and more sensitive identification of pathogenic fungi,
with antigen testing and nucleic acid detection showing the
most promising results [3–5]. In nucleic acid-based methods,
the internal transcribed spacer (ITS) region of the fungal
ribosomal RNA operon is one of the most commonly used
targets. The ITS region exists in multiple copies in the fungal
genome, and shows high interspecies sequence divergence
and low intraspecies sequence variation. Fungal identification
methods based on ITS include length polymorphism analysis
[6], sequence analysis [7,8], multiplex PCR [9,10], probe
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hybridization [11,12] and DNA array [13–15]. However, the
DNA array systems that have been developed so far, with a
maximum of 24 target species [16], are unable to cover the
large number of common and emerging fungal pathogens.
Also, the majority of the arrays have not been tested with
primary clinical specimens.
Recently, an oligonucleotide array system based on the
fungal ITS1 and ITS2 sequence has been developed [17,18].
The system comprises two arrays that can identify 77 yeast
species (16 genera) and 66 mould species (33 genera)
(Table 1), respectively. In previous studies, both arrays affor-
ded high sensitivity (100% and 98.3%, respectively) and speci-
ficity (97% and 98.1%, respectively) in identifying reference
strains and clinical isolates [17,18]. To test the feasibility of
the arrays in the clinical context, we prospectively analysed
positive blood culture samples with this array system, and com-
pared its performance with conventional diagnostic methods.
Materials and Methods
Collection of specimens
Fungal blood cultures obtained from February to July, 2008
at the National Taiwan University Hospital (a tertiary care
hospital with transplant services) were analysed. BACTEC
Myco/F Lytic bottles (Becton Dickinson Microbiology Sys-
tems, Sparks, MD, USA) containing 5–10 mL of blood from
patients, were incubated in the BACTEC 9240 culture sys-
tem at 37C. When growth in the bottles was detected,
smears were checked for the presence of fungi. Aliquots
from positive bottles were collected for the study. Isolates in
the positive bottles were also identified to the species level
by standard laboratory procedures, including morphological
identification and the VitekYBC.
To evaluate test specificity, six negative blood samples
were spiked with non-target strains obtained from Biore-
source Collection and Research Centre (BCRC; Hsinchu,
Taiwan) and Centraalbureau voor Schimmelcultures (CBS;
Utrecht, the Netherlands), including C. methanolovescens
BCRC 20476, C. mogii BCRC 21506T, Pichia henricii BCRC
22170, Trichosporon dermatis CBS 2043, T. mucoides CBS
7625, and Debaryomyces polymorphus BCRC 21478T, and
tested. In addition, 51 bacterium-positive blood cultures with
Staphylococcus aureus (n = 6), coagulase-negative staphylo-
cocci (n = 11), Streptococcus species (n = 2), Enterococcus spe-
cies (n = 2), Corynebacterium species (n = 3), Bacillus species
(n = 1), Listeria monocytogenes (n = 1), Escherichia coli (n = 6),
Klebsiella pneumoniae (n = 2), Enterobacter species (n = 3),
Serratia marcescens (n = 1), Salmonella species (n = 1), Aero-
monas hydrophila (n = 1), Pseudomonas aeruginosa (n = 2),
Acinetobacter baumannii (n = 5), Stenotrophomans maltophilia
(n = 1), and other glucose-non-fermenting Gram-negative
bacilli (n = 3) were tested.
Construction of the arrays
The species-specific and genus-specific oligonucleotide probes
(16- to 30-mers) were designed from either the ITS1 or the
ITS2 region of the fungal rRNA genes. In addition, a probe
designed from the 5.8S rRNA gene was used as a positive
control and a digoxigenin-labelled universal bacterial primer
6R was used as a position marker. The sequence of the indi-
vidual probes has been listed previously [17–19]. The probes
were spotted onto a positively charged nylon membrane as
400-lm-diameter dots as previously described [17,18]. The
layout of the probes on the arrays is shown in Fig. 1.
Isolation of fungal DNA from positive blood cultures
A 0.5-mL aliquot of blood-broth mixture from each positive
blood culture bottle was used for DNA extraction. Each ali-
quot was first centrifuged at 5000 g for 10 min. The pellet
was suspended in 6 U lytic enzyme solution (Qiagen, Taipei,
Taiwan) and incubated at 37C for 30 min. After further cen-
trifugation at 5000 g for 10 min, the pellet was extracted
using the Blood Genomic DNA Isolation kit (Onestar, Taipei,
Taiwan). All reagents were tested for the absence of fungal
DNA by PCR before use to avoid contamination.
PCR amplification and probe hybridization
Fungus-specific universal primers ITS1 (5¢-dig-TCC GTA
GGT GAA CCT GCG G-3¢) and ITS4 (5¢-dig-TCC TCC
GCT TAT TGA TAT GC-3¢) were used to amplify the
region spanning the ITS1, the 5.8S rRNA gene, the ITS2, and
partial regions of the 18S and 28S rRNA genes. Each primer
was labelled with a digoxigenin (dig) molecule at the 5¢ end.
The reaction mixtures and thermal conditions for PCR have
been described previously [18]. The amplicons were then
hybridized to the arrays as previously described [17].
Analysis of discrepant specimens
For samples in which the results obtained by identification
using conventional methods and those obtained by the oligo-
nucleotide array were discrepant, sequencing of the amplified
ITS region was performed. The determined sequence was then
compared with sequences available in the GenBank using the
BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Definition of sensitivity and specificity
Sensitivity was defined as the number of isolates correctly
identified by the array divided by the total number of isolates
identified by (repeated) conventional methods and sequence
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TABLE 1. Fungal species included in the arrays and their corresponding probe codes
Microorganism Probe code Microorganism Probe code
Yeast array Mould array
Candida albicans CAB5 Absidia corymbifera Abcor3
Candida boidinii CB1 Acremonium falciforme Acfal1
Candida cantarellii CCA1 Acremonium kiliense Ackil2
Candida catenulata CCT1 Acremonium kiliense Ackil3
Candida chodatii CCH3 Acremonium strictum Acstr2
Candida colliculosa CCO5b Alternaria alternata Alalt3
Candida dattila CDAT2a Aspergillus clavatus Ascla4
Candida dubliniensis CDU1a Aspergillus flavus Asfla4
Candida famata CFAM1a Aspergillus fumigatus Asfum2
Candida freyschussii CFRE2 Aspergillus nidulans Asnid2
Candida glabrata CGL1 Aspergillus niger Asnig2
Candida globosa CGLO1a Aspergillus terreus Aster2
Candida guilliermondii CGU2 Aspergillus versicolor Asver4
Candida haemulonii CHAE1a Aureobasidium pullulans Aupul2
Candida holmii CHO2 Aureobasidium pullulans Aupul3
Candida inconspicua CINC3 Aureobasidium pullulans Aupul4
Candida intermedia CIT2 Beauveria bassiana Bebas5
Candida kefyr CKEF2 Bipolaris spicifera Bispi
Candida krusei CK3 Blastomyces dermatitidis Blder2
Candida lambica CLAM3a Chaetomium cochliodes/C. globosum/C. funicola Chcgf1
Candida lipolytica CLI1a Chaetomium funicola Chfun2
Candida lusitaniae CLUS1 Cladophialophora bantiana Clban5
Candida maltosa CML4 Cladophialophora carrionii Clcar2
Candida melibiosica CMEL1 Cokeromyces recurvatus Corec2
Candida membranaefaciens CMB1 Cunninghamella bertholletiae Cuber3
Candida norvegensis CNO2b Cunninghamella spp. Cun4
Candida. norvegica CNOR1a Epidermophyton floccosum Epflo2c
Candida parapsilosis CP6,CP8,CP10 Exophiala dermatitidis Exder1
Candida pelliculosa CPEL3 Exophiala jeanselmei Exjea
Candida pintolopesii CPI2 Exophiala werneckii Exwer
Candida rugosa CRUG2 Fonsecaea compacta/F. pedrosoi Focp
Candida sake CSAK3 Fusarium moniliforme Fumon
Candida santamariae var. santamariae CSAN1 Fusarium moniliforme/F. oxysporum/F. pallidoroseum Fumop
Candida silvicola CSIL2 Fusarium solani Fusol2
Candida sphaerica CSPH3a Geotrichum candidum Gecan
Candida steatolytica CST3 Geotrichum capitatum Gecap3
Candida tropicalis CT3 Malbranchea filamentosa Mafil4
Candida utilis CUT5 Microsporum audouini Miaud3b
Candida valida CVAL2a Microsporum canis Mican2g
Candida viswanathii CVIS4 Microsporum cookei Micok4
Candida zeylanoides CZEY2d Microsporum ferrugineum Mifer1c
Arthroascus schoenii AS1 Microsporum gallinae Migal3
Cryptococcus albidus CAL5 Microsporum gypseum Migyp3b
Cryptococcus curvatus CCUR2 Microsporum gypseum Migyp5b
Cryptococcus laurentii CLR4 Microsporum nanum Minan1
Cryptococcus neoformans CN4b Microsporum persicolor Miper2
Cryptococcus uniguttulatus CUNI2 Paracoccidioides brasiliensis Pabra2
Debaryomyces marama DMAR2 Paecilomyces javanicuss Pajav
Dekkera bruxellensis DB3 Penicillium marneffei Pemar2
Endomyces fibuligera EF4 Phialophora richardsiae Phric3
Hansenula saturnus HS2 Phialophora verrucosa Phver3
Kloeckera apiculata KAP2 Piedriaia hortai var. hortai Pihor2
Kloeckera apis KAPIS2b Pseudallescheria boydii Psboy3
Kloeckera japonica KJAP1 Rhizopus oryzae Riory4
Kluyveromyces delphensis KDEL3 Rhizomucor pusillus Ripu4
Kluyveromyces yarrowii KYAR1 Scopulariopsis brevicaulis Scbre3
Lodderomyces elongisporus LEL2 Scedosporium prolificans Scpro4
Pichia carsonii PCAR1b Scytalidium dimidiatum/S. hyalinum Sydh
Pichia etchellsii PETC2 Trichophyton mentagrophytes Trmen2d
Pichia farinosa PF1 Trichophyton mentagrophytes Trmen3g
Pichia ohmeri PO2 Trichophyton rubrum Trrub3
Pichia spartinae PSPA3 Trichophyton soudanense Trrslc
Rhodotorula glutinis RGLU1 Trichophyton schoenleinii Trsch2b
Rhodotorula minuta RM4 Trichophyton terrestre Trter1
Rhodotorula rubra RRUB1 Trichophyton terrestre Trter6b
Saccharomyces cerevisiae SC2 Trichophyton tonsurans Trtonle
Saccharomyces kluyveri SKLU1 Trichophyton verrucosum Trver2e
Sporobolomyces salmonicolor SSAL3 Trichophyton violaceum Trviolc
Trichosporon aquatile TAQAS1/TAQU3 Ulocladium consortiale Ulcon2
Trichosporon asahii TAQAS1/TASA1b
Trichosporon cutaneum TCUT3b
Trichosporon inkin TAQAS1/TINK2
Trichosporon pullulans TP1
Zygosaccharomyces bisporus ZB5
Zygosaccharomyces cidri ZCI3
Zygosaccharomyces fermentati ZF6a
Zygosaccharomyces florentinus ZFLO1
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analysis. Specificity was defined as the number of spiked
blood samples and bacterium-positive blood cultures produc-
ing negative hybridization results divided by the total number
of blood samples tested.
Antifungal susceptibility testing
MICs were determined for all yeast isolates using the ATB
Fungus 3 strip (bioMe´rieux). The ATB Fungus 3 strip consists
of five antifungal agents at the following concentrations:
5-flucytosine 4 and 16 mg/L, amphotericin B 0.5–16 mg/L,
fluconazole 1–128 mg/L, itraconazole 0.125–4 mg/L, and
voriconazole 0.06–8 mg/L. The MICs were determined
according to the manufacturer’s instructions.
Results
Identification of fungi in positive blood cultures by
conventional methods and by oligonucleotide arrays
A total of 116 positive blood culture samples from 105
patients were analysed. The blood samples were taken from
peripheral sites (49, 42.2%), central vein catheters (35,
30.2%), arterial lines (16, 13.8%), port-A catheters (14,
12.1%), double-lumen catheters (1, 0.9%), and bone marrow
aspiration (1, 0.9%). From these samples, a total of 120 yeast
isolates and two mould isolates were identified by conven-
tional methods (Table 2).
Among the 116 positive blood cultures analysed by the
array, 111 samples yielded identifications consistent with those
obtained by conventional methods. Among the five samples
with discrepant results, four were detected as multiple species
fungaemia (MSF) by the array, but were reported as single-spe-
cies infection using conventional methods (Table 2). Conven-
tional isolation and identification were repeated in these four
samples and the presence of additional yeast species, the same
as that detected by the array, was confirmed in all four cul-
tures. The remaining discrepant sample was identified as con-
taining Rhodotorula mucilaginosa by the array, but was reported
as containing R. glutinis using the Vitek YBC. To differentiate
R. mucilaginosa from R. glutinis, the supplementary nitrate
assimilation test, which requires an incubation period of 4 days
and is not routinely performed in the clinical laboratory [20],
was required. Identification of the discrepant isolate as R. muci-
laginosa by the array was confirmed by sequence analysis of
1 2 3 4 5 6 7 8 9 10 11 12  
A CAB5 CB1 CCA1 CCT1 CCH3 CCO5b  M AS1 CAL5 CCUR2 CLR4 CN4b  
B CDAT2a CDU1a CFAM1a CFRE2 CGL1 CGLO1a  M CUNI2 DMAR4 DB3 EF4 HS2  
C CGU2 CHAE1a CHO2 CINC3 CIT2 CKEF2  M KAP2 KAPIS2b KJAP1 KDEL3 KYAR1  
D CK3 CLAM3a CLI1a CLUS1 CML4 CMEL1  M LEL2 PCAR1b PETC2 PF1  PC 
E M M M M M M NC  M M M M M 
F CMB1 CNO2b CNOR1a CP6 CP8 CP10  M PO2 PSPA3 RGLU1 RM4 RRUB1  
G CPEL3 CPI2 CRUG2 CSAK3 CSAN1 CSIL2  M SC2 SKLU1 SSAL3 ZB5 ZCI3  
H CSPH3a CST3 CT3 CUT5 CVAL2a CVIS4  M ZF6a ZFLO1 TAQAS1 TAQU3 TASA1b  
I PC  NC NC  NC  NC CZEY2d  M TCUT3b TINK2 TP1  NC  NC  
1 2 3 4 5 6 7 8 9 10 11  
A Abcor3 Acfal1 Ackil2 Ackil3 Acstr2  M Alalt3 Ascla4 Asfla4 Asfum2 Asnid2  
B Asnig2 Aster2 Asver4 Aupul2 Aupul3  M Aupul4 Bebas5 Bispi Blder2  PC 
C Chcgf1 Chfun2 Clban5 Clcar2 Corec2  M Cuber3 Cun4 Exder1 Exjea Exwer  
D Focp Fumon Fumop Fusol2 Gecan  M Gecap3 Mafil4 Pabra2 Pihor2 Pajav  
E Pemar2 Phric3 Phver3 Psboy3 Ripu4  M Riory4 Scbre3 Scpro4 Sydh Ulcon2  
F M M M M M NC  M M M M M 
G Epflo2c Miaud3b Mican2g Micok4 Mifer1c  M Migal3 Migyp3b Migyp5b Minan1 Miper2  
H Trmen2d Trmen3g Trrub3 Trrs1c Trsch2b  M Trter1 Trter6b Trton1e Trver2e Trvio1c  
(a) 
(b)
FIG. 1. Layout of oligonucleotide probes on the yeast (a) and mould (b) arrays. PC, positive control; NC, negative control; M, position marker.
The yeast array contained 108 spots, including 80 spots for identification of 77 species, two positive controls, seven negative controls (tracking
dye only), and 19 position markers. The mould array contained 88 spots, 69 spots for identification of 66 species, one positive control, one neg-
ative control and 17 position markers. The species corresponding to each probe code is listed in Table 1.
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the amplified ITS region using the BLAST program (GenBank
accession no. EU781664). Representative hybridization results
are shown in Fig. 2.
Performance of the array
Whereas the five discrepant samples were initially either
incorrectly or incompletely identified using conventional meth-
ods, the test sensitivity of the arrays was 100% (126/126).
All six blood samples spiked with non-target fungal species and
51 bacterium-positive blood cultures yielded negative hybridi-
zation results; thus the assay specificity was also 100% (57/57).
Time required from positive blood cultures to species
identification
From the time at which microbial growth was detected in
blood culture bottles, the identification of fungi could be
completed in 16–24 h using the oligonucleotide array,
regardless of the infecting species. No additional time was
required for mixed cultures. Conversely, identification of
fungal pathogens by conventional methods requires 2–6 days;
2–4 days for Candida species and 4–6 days for Cryptococcus
neoformans [21]. The identification of moulds requires
approximately 1–2 weeks or longer.
Antifungal susceptibility testing
Table 3 summarizes the in vitro susceptibility of Candida spp.
isolates to five antifungal agents. Among the four dual-species
cultures misidentified using conventional methods, in two
cases, both isolates were submitted to susceptibility analysis.
The additional isolate identified by the array had higher MIC
values in both samples. Specimen no. 84 yielded C. glabrata
(fluconazole MIC 4 mg/L) in addition to C. albicans (MIC
£1 mg/L), and specimen no. 42 yielded T. asahii (MIC 2 mg/L)
in addition to C. tropicalis (MIC £1 mg/L).
Treatment outcome of patients with discrepant culture
results
The four MSFs (patients 1–4) were all catheter-related infec-
tions (Table 4). In patients 2 and 3, the MICs for both of the
dual isolates were determined (sample no. 84B and 42B; see
above). Although the C. glabrata isolate from patient 2 had a
higher fluconazole MIC value (4 mg/L), a second blood culture
obtained after 10 days of fluconazole treatment yielded no fun-
gal growth. In patient 3, a second blood culture (not included
in this study), drawn 2 days after fluconazole treatment,
yielded both C. tropicalis and T. asahii using conventional meth-
ods. Antifungal therapy was thus shifted to amphotericin B.
The patient died 10 days later despite treatment adjustment.
Discussion
This report describes the use of an oligonucleotide array
system to identify fungal pathogens in positive blood cultures.
TABLE 2. Comparative identification of fungal species in
positive blood culture bottles using phenotypic methods
and the oligonucleotide array
Species
No. of isolates
identified using
phenotypic
methods (%)
No. of isolates
identified using
the oligonucleotide
array (%)
Candida albicans 49 (37.9) 50 (39.7)
C. tropicalis 25 (18.1) 26 (20.6)
C. glabrata 17 (13.8) 18 (14.3)
C. parapsilosis 14 (11.2) 14 (11.1)
C. guilliermondii 1 (0.9) 1 (0.8)
C. lusitaniae 1 (0.9) 1 (0.8)
C. intermedia 1 (0.9) 1 (0.8)
Cryptococcus neoformans 9 (7.8) 9 (7.1)
Penicillium marneffei 2 (1.7) 2 (1.6)
Trichosporon asahii 1 (0.9) 2 (1.6)
Rhodotorula mucilaginosa 1 (0.9) 2 (1.6)
R. glutinis 1 (0.9) 0
Total 122 126
Mixed cultures
C. albicans + C. tropicalis 4 6
C. albicans + C. glabrata 1 2
C. glabrata + C. parapsilo-
sis
1 1
C. tropicalis + T. asahii 0 1
Total 6 10
Candida albicans C. guilliermondii
C. lusitaniae C. intermedia Cryp. neoformans Trichosporon asahii Rhodotorula 
mucilaginosa
    
C. albicans +
C. tropicalis
C. albicans +  
C. glabrata
C. glabrata + 
C. parapsilosis 
C. tropicalis +
T. asahii
Penicillium marneffei
C. parapsilosisC. glabrataC. tropicalis
FIG. 2. Representative hybridization results.
All isolates were hybridized to the yeast array
except for Penicillium marneffei, which is
hybridized to the mould array.
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A test sensitivity of 100% (126/126) and specificity of 100%
(57/57) were obtained. The present method has previously
been validated by testing pure cultures, and a detection limit
of 10 pg DNA per assay [17,18], approximately equal to 250
cells of C. albicans (37 fg of DNA per cell) [14], was
achieved. From the time at which a blood culture becomes
positive, use of the array decreased the time for identifica-
tion to 16–24 h. The reduction in time is even more promi-
nent when moulds are the infecting organism, or when
supplementary tests are required for definite identification.
Candida spp. are the fourth most frequent cause of blood-
stream infection, with a mortality rate ranging from 30 to
50% [22]. In this study, Candida spp. accounted for 88.1%
(111/126) of the isolates identified, and 55.0% (61/111) of
these isolates were non-albicans species. Inadequate antimi-
crobial therapy has been found to be an independent deter-
minant of outcome in patients with severe infection [23].
Using conventional methods, Candida species with reduced
antifungal susceptibility, such as C. glabrata and C. krusei,
often require a longer time for identification. Since species-
TABLE 4. Summary of cases with discrepant identification results using the array and conventional methods
Sample
no.
Age/
gender Underlying condition(s)
Source(s) of
fungaemia
Identification
by conventional
methods
Identification
by array
Final
identificationa Antifungal treatment
83B 52/M Cardiac myxoma with aortic
embolus, s/p thrombectomy;
CVC Candida albicans C. albicans
+ C. tropicalis
C. albicans
+ C. tropicalis
Fluconazole 200 mg qd for 11 days
84b 58/F Breast cancer with lung, liver,
and bone metastasis
CVC C. albicans C. albicans
+ C. glabrata
C. albicans
+ C. glabrata
Fluconazole 200 mg qd for 10 days
42b 31/M Nasopharyngeal carcinoma
with brain metastasis
CVC C. tropicalis C. tropicalis
+ Trichosporon
asahii
C. tropicalis
+ T. asahii
Fluconazole 400 mg qd for 10 days,
followed by amphotericin B 50 mg
qd for 10 days
59A 82/F ESRD with PD peritonitis,
pulmonary fibrosis
CVC, arterial
line
C. tropicalis C. albicans
+ C. tropicalis
C. albicans
+ C. tropicalis
Not given (positive culture drawn
the day before death)
71 50/M Myelodysplasia syndrome,
RAEB-1
unknown Rhodotorula glutinisc R. mucilaginosa R. mucilaginosad Fluconazole 400 mg qd for 3 days,
then amphotericin B 50 mg qd for
5 days, followed by liposomal AMB
50 mg qd for 4 days
ESRD, end-stage renal disease; PD, peritoneal dialysis; RAEB, refractory anaemia with excess blasts; CVC: central venous catheter; AMB, amphotericin B.
aFinal identification was achieved by repeated isolation from the positive blood cultures and identification by conventional methods; the identification of Rhodotorula mucilagin-
osa was made by ITS sequence analysis.
bSpecimen with both isolates obtained for MIC analysis.
cR. glutinis was reported based on interpretation of the Vitek test. Supplementary tests required to differentiate between R. glutinis and R. mucilaginosa were not routinely per-
formed at our hospital.
dGenBank accession number EU781664 (100%/100%).
TABLE 3. In vitro susceptibility of Candida spp. isolates to five antifungal agents
Species (no. of isolates)
MIC (mg/L) Susceptibility category (%)
Antifungal agent Range MIC50 MIC90 I or S-DD
a Ra
Candida
albicans
(45)
5FC £4 £4 £4 0 0
AMB £0.5 £0.5 £0.5 – 0
FCA £1 £1 £1 0 0
ITR £0.125 £0.125 £0.125 0 0
VRC £0.06 £0.06 £0.06 0 0
C. tropicalis
(26)
5FC £4 to >16 £4 >16 0 19.2
AMB £0.5–1 £0.5 1 – 0
FCA £1–2 £1 2 0 0
ITR £0.125–1 0.25 0.5 73.1 3.8
VRC £0.06–0.25 0.125 0.25 0 0
C. glabrata
(17)
5FC £4 £4 £4 0 0
AMB £0.5–1 £0.5 1 – 0
FCA 4–64 8 16 41.2 5.9
ITR 1–>4 >4 >4 0 100
VRC 0.25–4 0.5 2 23.5 5.9
C. parapsilosis
(14)
5FC £4 £4 £4 0 0
AMB £0.5–1 £0.5 1 – 0
FCA £1–8 £1 2 0 0
ITR £0.125–0.25 £0.125 0.25 14.3 0
VRC £0.06–0.25 £0.06 0.125 0 0
AMB, amphotericin B; FCA, fluconazole; 5FC, 5-flucytosine; ITR, itraconazole; VRC, voriconazole; MIC50, minimum concentration that inhibits 50% of isolates tested; MIC90,
minimum concentration that inhibits 90% of isolates tested.
aInterpretive MIC breakpoints for susceptibility were in accordance with those published by NCCLS [28] and previous studies [29,30]. I or S-DD, intermediate or suscepti-
ble-dose dependent: 5FC, 8–16 mg/L; AMB, not defined; FCA, 16–32 mg/L; ITR, 0.25–0.5 mg/L; VRC, 2 mg/L. R, resistant: 5FC, ‡32 mg/L; AMB, ‡2 mg/L; FCA, ‡64 mg/L;
ITR, ‡1 mg/L; VRC, ‡4 mg/L.
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level identification is usually sufficient for predicting antifungal
susceptibility, rapid identification, regardless of the causative
pathogens, could improve both the timing and selection of
effective therapy.
In the present study, the oligonucleotide array detected
MSF in ten samples, as opposed to six detected by conven-
tional methods. The majority of cases (9/10) were multiple
species candidaemia (MSC). The clinical features, causative
pathogens, and mortality rate of patients with MSC were
found to be similar to those in patients with monomicrobial
candidaemia [24]. In this study, the incidence of MSC was
8.6% (9/105). This is higher than that reported in previous
studies, which mostly ranged from 3 to 6% [24,25]. This may
indicate that the oligonucleotide array is a more sensitive
tool in detecting yeasts that are less abundant. It also sug-
gests that the occurrence of MSC may be underestimated by
using routine methods. Considering the variation in antifungal
susceptibility of different Candida species, complete identifica-
tion in cases of multiple species infection has important ther-
apeutic implications. It was demonstrated in this study that,
using the array, an additional isolate was detected in two
samples identified as monomicrobial infection, and the MICs
were higher in the missed isolates.
In addition to yeasts, the array revealed two isolates of
Penicillium marneffei in blood samples from AIDS patients.
Penicillium marneffei has emerged as a major opportunistic
pathogen that causes invasive infection among HIV-infected
patients in Southeast Asia [26]. In Taiwan, the number of
P. marneffei infections has increased remarkably in the past
decade, with the majority considered to be indigenously
acquired [27]. Infection with P. marneffei is associated with
high morbidity and mortality [26]. Unfortunately, the diagno-
sis of penicilliosis remains problematic. The oligonucleotide
array described here allows rapid, molecular-based identifica-
tion of moulds, circumventing the time-consuming subculture
procedures of phenotypic tests.
Several other groups have previously described the appli-
cation of DNA array technology to fungal identification. In
the microarray developed by Leinberger et al. [14], capture
probes complementary to ITS regions were used to detect
12 Candida and Aspergillus species. Other clinically relevant
genera were not included. In a second study by Huang et al.
[13], capture probes complementary to the ITS2 region
were used to detect 20 species (eight genera) of yeasts and
moulds. Campa et al. [16] described a DNA microarray
method based on the arrayed-primer extension technique
targeting 24 fungal species, including C. famata, T. cutaneum,
Fusarium solani and P. marneffei. All of these emerging species
are included in the present array system. The aforemen-
tioned methods were all tested with standard strains and
clinical isolates, while blood samples spiked with fungi were
additionally analysed by Huang et al. No primary clinical spec-
imens have been tested [13,14]. Another study by Spiess
et al. [15] utilized a DNA microarray targeting the ITS1
region of 14 fungal pathogens. Non-cultured clinical samples
from neutropenic patients were analysed. However, emerg-
ing and clinically important fungal pathogens, such as C. krusei
and P. marneffei, were not included. Furthermore, a common
limitation of these microarray-based methods lies in the fact
that microarray reading systems, i.e. fluorescence detection
apparatus, are not standard equipment in clinical laborato-
ries. However, colorimetric detection was used in this study,
with the hybridized dots (400 lm in diameter) being read-
able by the naked eye.
There are several limitations to this study. First, the
number of specimens containing mould was very limited.
Further studies are required to evaluate the performance
of the array in mould identification. Second, only isolates
from blood cultures were analysed; it remains to be
determined whether other clinical specimens could be
analysed. Third, because of limited data in the present
study, the clinical significance of early detection of MSF
remains to be clarified.
In conclusion, the present oligonucleotide array system
allows rapid and reliable identification of a vast number of
fungal pathogens in positive blood cultures. In addition, the
array method is more sensitive than conventional methods
in detecting MSF.
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